ClinicalTrials.gg
CompletedNCT04202003Updated Apr 15, 2024

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Phase 1/2 interventional study of TJ011133 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes(MDS), sponsored by TJ Biopharma Co., Ltd.. Completed at 26 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by TJ Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
120th of 433
105 · median 50
Started
2020
with 24 others
Phase 1/2
66 of 473
39 open now
Registered
97th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 120th largest by enrollment of the 433 interventional ones that give a count, is one of 25 that started in 2020, is one of 66 in phase 1/2, and was the 97th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study is a phase I/II study of TJ011133 as Monotherapy and in Combination with Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). This study include Phase I and Phase IIa study. Phase I study ClinicalTrials.gov ID is NCT04202003 and this is for phase IIa study. Phase IIa study is designed to preliminarily assess the efficacy and safety of TJ011133 in combination with AZA as first-line treatment in patients with newly diagnosed AML who are intolerant to standard induction chemotherapy or patients with treatment naive, intermediate and high-risk MDS.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndromes(MDS)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1 single dose escalation:

  • Male or female, aged ≥ 18 and ≤ 70 years at the time of signing form;
  • For the disease under study, enrollment may be considered if one of the following is satisfied:

    1. Subjects must be with diagnosed as acute myeloid leukemia (AML) according World Health Organization (WHO) 2016 classification criteria, with the exception of acute promyelocytic leukemia; it is a recurrent or disease without other available appropriate conventional treatments;
    2. Subjects with intermediate- and high-risk relapsed/refractory MDS (IPSS-R score >3.5) who are pathologically confirmed and meeting the diagnostic criteria of World Health Organization (WHO) 2016 or who are unable to tolerate the treatment of demethylation drugs or other drugs (e.g., treatment-emergent Grade 3 or higher drug-related hepatic and/or renal toxicities leading to permanent withdrawal during treatment), and the investigator judges that there is no other appropriate treatment;
  • For patients with MDS, a blast percentage of \< 20% is required in bone marrow aspiration smear or bone marrow pathology at screening;
  • score 0-2;
  • Subjects have been recovered from the toxicity of previous anti-AML/MDS treatments (according to NCI CTC AE 5.0 ≤ Grade 1, except alopecia) ;
  • Subjects must have adequate liver function, renal function and coagulation function. The laboratory tests within 7 days before the first dose should meet the following requirements:

    1. Liver function:

      • Serum total ≤ 1.5 × (ULN);
      • and ALT ≤ 2.5 × ULN.
    2. Renal function:

      -Serum creatinine ≤ 1.5 × ULN or estimated ≥ 50 mL/min according to the Cockcroft-Gault equation (Appendix 5).

    3. Coagulation function:

      • (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
      • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.

Subjects for Phase 2a combination therapy:

  • Male or female, aged ≥ 18 years at the time of signing informed consent form;
  • For the disease under study, enrollment may be considered only if the following conditions are met:

Newly diagnosed AML with intolerance to standard induction chemotherapy/intermediate- and high-risk (International Prognostic Scoring System IPSS-R) MDS (only applicable for Phase 2a study); symptomatic treatment such as hydroxycarbamide, erythropoietin, and/or hematopoietic growth factors are allowed within 7 days of the first dose;

  • The subject's ECOG score has to meet the following criteria:

    • Newly diagnosed AML with intolerance to standard induction

      • Newly diagnosed intermediate- and high-risk MDS: ECOG score 0 - 2
  • Subjects must have adequate liver function, renal function and coagulation function. The laboratory tests within 7 days before the first dose should meet the following requirements::

    1. Liver function:

      • Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN); total bilirubin ≤ 3 × ULN is allowed for subjects aged 18 - 74 years (only for newly diagnosed AML subjects who are intolerant to standard induction chemotherapy)
      • AST and ALT ≤ 3 × ULN.
    2. Renal function:

      -Estimated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault equation (Appendix 5); creatinine clearance ≥ 30 mL/min is allowed for subjects aged 18 - 74 years (only for newly diagnosed AML subjects who are intolerant to standard induction chemotherapy)

    3. Coagulation function:

      • International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN;
      • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.

All subjects:

  • Expected survival ≥ 12 weeks;
  • White blood cell count (WBC) ≤ 25 × 103/μL within 7 days prior to the first dose (hydroxycarbamide or leukapheresis is allowed to meet this criterion);
  • Subjects must be willing to provide available diagnostic evidence or undergo bone marrow aspiration and biopsy before study treatment, and must be willing to undergo bone marrow aspiration and biopsy after receiving study treatment;
  • Subjects must give informed consent before starting the study and sign written consent voluntarily by themselves (or their legal representatives). Subjects or their legal representatives should be able to communicate well with investigators and agree to adhere with the study protocol and complete the study.

Exclusion criteria

Exclusion Criteria

Phase 1 single dose escalation:

  • Previously received treatment with other drug therapies targeting 7;
  • Previously received CAR-T cell therapy;
  • Previously received treatment with PD1 or PDL1 antibody;
  • Previously received or planned to receive stem cell transplantation during the study, or autologous stem cell transplantation within 3 months prior to the first dose of study drug;
  • Subjects have received chemotherapy, immunotherapy, radiotherapy, major surgery within 4 weeks prior to the first dose;
  • Subjects' cardiac function meet any of the following criteria:

    • Subjects have any kind of rhythm abnormalities or conduction abnormalities that require clinical intervention;
    • Subjects have congenital syndrome or QTc > 450 msec in men, QTc > 470 msec in women (QTc calculated using Fridericia's correction formula [Appendix 6]), or on medications that may cause QT prolongation or torsades de pointes;
    • Subjects have any kind of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery or peripheral artery bypass surgery, cerebrovascular events (thromboembolic or hemorrhagic cerebrovascular events, excluding ), (NYHA) (Appendix 7) ≥ Grade 3 congestive cardiac failure, or (LVEF) \< 40% within 3 months prior to enrollment; Phase 2a combination therapy
  • Previously received treatment with demethylated drugs or cytotoxic drugs in patients with MDS;
  • Previously received any anti-tumor therapy for AML;
  • AML with a good prognosis, including cytogenetic alterations, such as t (8;21), inv (16) or t (16;16) or t (15;17);
  • Subjects are known to have allergy to AZA or mannitol;
  • Subjects' cardiac function meet any of the following criteria:

    • Subjects have any kind of clinically significant rhythm abnormalities or conduction abnormalities that require clinical intervention;
    • Subjects have congenital QT prolongation syndrome or taking drugs that may cause QT prolongation or torsades de pointes;
    • Subjects have any kind of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery or peripheral artery bypass surgery, cerebrovascular events (thromboembolic or hemorrhagic cerebrovascular events, excluding transient ischemic attack), New York Heart Association (NYHA) (Appendix 7) ≥ Grade 3 congestive cardiac failure within 3 months prior to enrollment;
  • Subjects have undergone major surgery within 4 weeks prior to the first dose;

All subjects:

  • Subjects have received vaccination within 4 weeks prior to the first dose and/or planned vaccination after participating in the study;
  • Subjects have received clinical trial drug treatment within 4 weeks prior to the first dose or currently participating in other interventional clinical trials;
  • Subjects are known to have hereditary or acquired hemorrhagic disorders;
  • Subjects have hypertension uncontrollable with drug therapy (systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg at rest);
  • Subjects suffer from disease that requires long-term use of systemic therapy or other therapy. However, subjects who use physiologic replacement doses of hydrocortisone or drugs of equivalent doses (Appendix 8), i.e., up to 20 mg of hydrocortisone (or 5 mg of prednisone) in the morning and up to 10 mg of hydrocortisone (or 2.5 mg of prednisone) at night, may be considered for enrollment;
  • Subjects are known to have central nervous system (CNS) involvement;
  • Subjects are known to have infection (anti-HIV positive), active (HBsAg positive, or HBcAb positive and HBV-DNA PCR positive), or active (anti-HCV antibody positive and HCV-RNA PCR positive), or syphilis infection (anti-TP test positive);
  • Subjects have a history of solid organ transplantation;
  • Subjects plan to receive other anti-tumor therapies, including but not limited to chemotherapy, biotherapy, immunotherapy, hormone therapy and traditional Chinese medicine, while participating in the study;
  • Subjects have a history of disease or active autoimmune disease;
  • Subjects have uncontrolled active infection;
  • Subjects have severe electrolyte disturbances that cannot be corrected;
  • Subjects have a history of other , except for clinically cured malignancies (no relapse for at least 5 years), cured carcinoma in situ, and skin cancer other than malignant melanoma;
  • Subjects have a history of psychotropic drug abuse and are unable to quit or have mental disorders, or have concomitant diseases that seriously endanger patients' safety or hinder the study completion at the discretion of investigators;
  • Subjects are women during pregnancy or lactation, or women and men with fertility planning;
  • The investigators consider that patients have other factors that may affect the results of the study and interfere with their full participation in the study, including previous or existing health conditions or medical or laboratory abnormalities, or put them at high risk.
  • Subjects with MDS who meet any of the following must also be excluded:
  • Subjects have uncorrected serum folic acid deficiency or vitamin B12 deficiency;
  • MDS transformed from previously existing myeloproliferative tumors (MPN) or MDS/MPN types conforming to WHO 2016 classification standard include chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML), etc..
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    TJ011133

    This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.

    Drug: TJ011133

Interventions

  • DrugLemzoparlimabStudies of LemzoparlimabLemzoparlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities(DLT)

    To evaluate the safety and tolerance of TJ011133 monotherapy in patients with r/r AML or MDS

    Time frame: 28days after first dose

  2. Maximum tolerable dose(MTD)

    To explore the maximum tolerable dose (MTD) of TJ011133 monotherapy for patients with r/r AML or MDS, the recommended phase II dose (RP2D) and the optimal dosage regimen.

    Time frame: Through study completion, an average of 1 year

  3. Recommended phase II dose

    Recommended phase II dose (RP2D)

    Time frame: Through study completion, an average of 1 year

  4. Complete response rate (CR rate) only for phase 2a

    Preliminary efficacy endpoints (only for Phase 2a): for response assessment in AML/MDS patients, the complete response rate (CR rate) will be evaluated according to the ELN2017/IWG 2006 criteria

    Time frame: Through study completion,an average of 1 year

07

Study locations

26 sites
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Peking University International Hospital
    Beijing, Beijing 102206, China
  • Beijing Boren Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
  • Zhujiang Hospital Of Southern Medical University
    Guangzhou, Guangdong 510280, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510515, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518020, China
  • The Affiliated Hospital of Guizhou Medical University
    Guiyang, Guizhou 550004, China
  • The Second Hospital of HeBei Medical University
    Shijiazhuang, Hebei 050000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Jiangsu Province Hospital
    Suzhou, Jiangsu 221006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 266000, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200000, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai 200233, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)
    Xi'an, Shanxi 710004, China
  • Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical
    Tianjin, Tianjin 300020, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • The second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650101, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Dec 2023, 44 months.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's 44 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2019
First posted
Dec 17, 2019
StartActual
Mar 25, 2020
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04202003
Lead sponsor
TJ Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Dec 17, 2019
Start date
Mar 25, 2020
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Last update
Apr 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lemzoparlimab

Start the discussion